C4 Therapeutics, Inc. (CCCC): Insider Trading, Congress Trades & Research | Tormere
CCCC
$3.10+5.08%
C4 Therapeutics, Inc.
Market Cap
$407M
Live price × SEC shares (Oct 30, 2026)
Sector
Health Care
Industry
Biotechnology
Beta (raw)
3.11
60mo monthly vs SPY
P/E (TTM)
N/M
TTM to Sep 2026 · negative earnings
P/S (TTM)
12.6
TTM to Sep 2026 · revenue
P/B
1.8
Mkt cap / shareholders' equity
EV/EBITDA (TTM)
—
EV / TTM EBITDA
Loading…
Financial Statements
USD thousands
Q4 FY2025
Dec 31, 2025
Q1 FY2026
Mar 31, 2026
Q2 FY2026
Jun 30, 2026
Q3 FY2026
Sep 30, 2026
TTM
Sep 30, 2026
Revenue
11,016
6,152
6,641
8,468
32,277
Research & development
24,982
24,606
24,471
24,803
98,862
Total operating expenses
34,161
33,937
33,064
33,064
134,226
Operating income
(23,145)
(27,785)
(26,423)
(24,596)
(101,949)
Pretax income
(20,365)
Income tax
121
0
0
0
121
Net income
(20,486)
(25,129)
(23,635)
(21,843)
(91,093)
EPS (basic) ($)
(0.20)
(0.18)
(0.16)
—
EPS (diluted) ($)
(0.20)
(0.18)
(0.16)
—
Weighted avg. shares (basic)
126,075
130,697
136,081
Weighted avg. shares (diluted)
126,075
130,697
136,081
Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Nov 5, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source
Showing the last 5 quarters. 25 more quarters, back to Sep 2019, with Tormere Pro.
